BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 10684624)

  • 21. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.
    Balzarini J; Karlsson A; Vandamme AM; Pérez-Pérez MJ; Zhang H; Vrang L; Oberg B; Bäckbro K; Unge T; San-Félix A
    Proc Natl Acad Sci U S A; 1993 Aug; 90(15):6952-6. PubMed ID: 7688467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of amino acid residues in the human immunodeficiency virus type-1 reverse transcriptase tryptophan-repeat motif that are required for subunit interaction using infectious virions.
    Mulky A; Sarafianos SG; Jia Y; Arnold E; Kappes JC
    J Mol Biol; 2005 Jun; 349(4):673-84. PubMed ID: 15893326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
    Ren J; Nichols CE; Stamp A; Chamberlain PP; Ferris R; Weaver KL; Short SA; Stammers DK
    FEBS J; 2006 Aug; 273(16):3850-60. PubMed ID: 16911530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer.
    Harris D; Lee R; Misra HS; Pandey PK; Pandey VN
    Biochemistry; 1998 Apr; 37(17):5903-8. PubMed ID: 9558323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intramolecular chimeras of the p51 subunit between HIV-1 and FIV reverse transcriptases suggest a stabilizing function for the p66 subunit in the heterodimeric enzyme.
    Tasara T; Amacker M; Hübscher U
    Biochemistry; 1999 Feb; 38(5):1633-42. PubMed ID: 9931031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues.
    Balzarini J; Velazquez S; San-Felix A; Karlsson A; Perez-Perez MJ; Camarasa MJ; De Clercq E
    Mol Pharmacol; 1993 Jan; 43(1):109-14. PubMed ID: 7678689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase.
    Tachedjian G; Orlova M; Sarafianos SG; Arnold E; Goff SP
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7188-93. PubMed ID: 11416202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical mechanism of HIV-1 resistance to rilpivirine.
    Singh K; Marchand B; Rai DK; Sharma B; Michailidis E; Ryan EM; Matzek KB; Leslie MD; Hagedorn AN; Li Z; Norden PR; Hachiya A; Parniak MA; Xu HT; Wainberg MA; Sarafianos SG
    J Biol Chem; 2012 Nov; 287(45):38110-23. PubMed ID: 22955279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subunit-specific analysis of the human immunodeficiency virus type 1 reverse transcriptase in vivo.
    Mulky A; Sarafianos SG; Arnold E; Wu X; Kappes JC
    J Virol; 2004 Jul; 78(13):7089-96. PubMed ID: 15194785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity.
    Alvarez R; Velázquez S; San-Félix A; Aquaro S; De Clercq E; Perno CF; Karlsson A; Balzarini J; Camarasa MJ
    J Med Chem; 1994 Nov; 37(24):4185-94. PubMed ID: 7527463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric HIV-1 and feline immunodeficiency virus reverse transcriptases: critical role of the p51 subunit in the structural integrity of heterodimeric lentiviral DNA polymerases.
    Amacker M; Hübscher U
    J Mol Biol; 1998 May; 278(4):757-65. PubMed ID: 9614940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of amino acids in the beta7-beta8 loop of human immunodeficiency virus type 1 reverse transcriptase for their role in virus replication.
    Mulky A; Vu BC; Conway JA; Hughes SH; Kappes JC
    J Mol Biol; 2007 Feb; 365(5):1368-78. PubMed ID: 17141805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Collective motions in HIV-1 reverse transcriptase: examination of flexibility and enzyme function.
    Bahar I; Erman B; Jernigan RL; Atilgan AR; Covell DG
    J Mol Biol; 1999 Jan; 285(3):1023-37. PubMed ID: 9887265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.
    Borkow G; Arion D; Wainberg MA; Parniak MA
    Antimicrob Agents Chemother; 1999 Feb; 43(2):259-63. PubMed ID: 9925515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
    Das K; Bauman JD; Rim AS; Dharia C; Clark AD; Camarasa MJ; Balzarini J; Arnold E
    J Med Chem; 2011 Apr; 54(8):2727-37. PubMed ID: 21446702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions.
    Olivares I; Mulky A; Boross PI; Tözsér J; Kappes JC; López-Galíndez C; Menéndez-Arias L
    J Mol Biol; 2007 Sep; 372(2):369-81. PubMed ID: 17651754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small molecule inhibitors targeting HIV-1 reverse transcriptase dimerization.
    Grohmann D; Corradi V; Elbasyouny M; Baude A; Horenkamp F; Laufer SD; Manetti F; Botta M; Restle T
    Chembiochem; 2008 Apr; 9(6):916-22. PubMed ID: 18318036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability.
    Figueiredo A; Zelina S; Sluis-Cremer N; Tachedjian G
    Curr HIV Res; 2008 Mar; 6(2):130-7. PubMed ID: 18336260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors.
    Auwerx J; North TW; Preston BD; Klarmann GJ; De Clercq E; Balzarini J
    Mol Pharmacol; 2002 Feb; 61(2):400-6. PubMed ID: 11809865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T).
    Balzarini J; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; Bathurst IC; Barr PJ; De Clercq E
    J Biol Chem; 1992 Jun; 267(17):11831-8. PubMed ID: 1376314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.